Induced Neuroprotection Independently From PrPSc Accumulation in a Mouse Model for Prion Disease Treated With Simvastatin

Yaron Haviv, DMD; Dana Avrahami, MSc; Haim Ovadia, PhD; Tamir Ben-Hur, MD, PhD; Ruth Gabizon, PhD; Ronit Sharon, PhD

Background: The misfolding and aggregation of specific proteins has emerged as a key feature of several neurodegenerative diseases. In prion diseases, progressive disease and neuronal loss are associated with the accumulation of PrPSc, the misfolded isoform of PrPC. Previous in vitro studies suggest that cholesterol-lowering drugs inhibit the conversion of PrPC to PrPSc and the accumulation of the latter, possibly through the disturbance of cholesterol-rich membrane domains (lipid rafts).

Objective: To examine the effect of simvastatin, a cholesterol-lowering drug, on prion disease progression and survival.

Design: Controlled animal study.

Setting: University medical center research laboratory.

Subjects: Female mice from the FVB/N strain.

Interventions: Peripheral and central nervous system inoculations with scrapie Rocky Mountain Laboratory inoculum.

Main Outcome Measures: Clinical, immunological, pathological, and molecular assays were performed.

Results: Simvastatin delayed disease progression, leading to increased survival in peripheral as well as central nervous system inoculations. Simvastatin’s beneficial effect is mediated through the L-mevalonate pathway; however, it is independent of brain cholesterol levels. Interestingly, simvastatin treatment induced PrPSc accumulation in parallel with an induced neuroprotective effect. In accordance, we found that simvastatin induced immunomodulatory mechanisms in the brains of infected mice, affecting expression levels of specific microglial chemokines and cytokines.

Conclusions: Simvastatin delays prion disease progression and increases survival in vivo, independently of the pathogenic conversion of PrPC to PrPSc. We show that simvastatin’s effects on neuroprotection are correlated with downregulation of Cox2 levels and induction of microglial activation in prion-infected mouse brains.

Arch Neurol. 2008;65(6):762-775

Prion diseases are a group of fatal neurodegenerative disorders characterized by the accumulation of PrPSc. PrPSc is a posttranslational refolded protein generated from the normal cellular prion protein PrPC. PrPC is attached to membranes through its glycosylphosphatidylinositol (GPI) anchor, which localizes PrPC to specific membrane microdomains enriched with cholesterol and sphingomyelin, known as lipid rafts.1-6

It has been suggested that the interaction of PrPC with membranes may play a role in the pathogenic conversion of PrPC to PrPSc. Several lines of evidence implicate lipid rafts in the conversion of PrPC to PrPSc.7 Specifically, PrPC and PrPSc colocalize to rafts, and cholesterol depletion from rafts decreases PrPSc formation in prion-infected cell lines.8-10 The localization into lipid rafts is important for PrPSc conversion. It was shown that replacing the GPI anchor with a transmembrane domain inhibited both PrPSc localization to rafts and conversion to PrPSc in cells infected with prions.8,11,12 These in vitro results suggested that cholesterol in rafts might play a role in disease pathogenesis.

In prion diseases, the interval between inoculation and appearance of a clinical disease is termed the incubation period, during which neurological and biochemical changes as well as accumulation of PrPSc in the brain can be detected. This stage can be designated a preclinical stage, which is characterized by the accumulation of the neurotoxic agent(s) to subpathological levels. Accordingly, a preclinical stage occurs in other neurodegenerative diseases such as...
Parkinson disease and Alzheimer disease. In Parkinson disease, for example, it has been shown that symptoms appear only at a late stage, when about 70% of the dopaminergic neurons are degenerated. Therefore, delayed disease progression may serve as a potential therapeutic approach in neurodegeneration.

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) inhibit the synthesis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and its conversion into l-mevalonate, thereby inhibiting the synthesis of all mevalonate pathway products that are mediators in cholesterol biosynthesis. Recent data suggested that statins have pleiotropic effects including neuroprotection in neurodegenerative diseases such as Alzheimer disease, multiple sclerosis, stroke, and prion diseases. Although statins have pleiotropic effects including neuroprotection, recent data suggested that statins have pleiotropic effects including neuroprotection in neurodegenerative diseases such as Alzheimer disease, multiple sclerosis, stroke, and prion diseases.

Here we used prion disease as a model for progressive neurodegeneration and tested the effect of simvastatin on prion disease progression, PrPSc levels, and neurotoxic effects in mice infected with the scrapie Rocky Mountain Laboratory (RML) strain. We show that simvastatin significantly delayed time of death in prion-infected mice (either intracerebrally or intraperitoneally) by virtue of its effect on prolonged incubation time. Surprisingly, the delayed onset is associated with higher levels of the pathogenic PrPSc form. No effect on brain cholesterol content was detected, but we show that simvastatin acted exclusively through the l-mevalonate pathway. Examinations of the treated and untreated scrapie-infected brains revealed that the beneficial effects of simvastatin involved reduced neuronal loss in specific brain regions. We show that simvastatin acted to modulate inflammatory mechanisms and downregulate Cox2 levels.

METHODS

ANIMALS

Animals were housed at a specific-pathogen-free, temperature-controlled room (22°C ± 1°C) with a cycle of light for 12 hours and dark for 12 hours (lights on at 06:00 hours) and free access to food and water. All of the animal procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the institute research committee.

PREPARATION OF THE RML STANDARD INOCULUM

Mouse-adapted scrapie prion inoculum was prepared from brains of scrapie-sick FVB/N mice (mean [SD] incubation time, 140 [15] days) as described previously. Brains were homogenized (1:10 wt/vol) by 10 strokes of a dounce homogenizer in buffer containing 10 mM TRIS hydrochloride at pH 7.4; 300 mM sucrose; 5 mM EDTA; 1 mM magnesium chloride; and protease inhibitor cocktail (Sigma, Rehovot, Israel). The homogenate was spun at 1000g for 5 minutes at 4°C, and the supernatant was divided in aliquots and kept at −70°C. This 10% brain homogenate was then diluted by 10-folds in bovine serum albumin, 1%, in phosphate-buffered saline. The FVB/N/nude male mice (Harlan, Rehovot) were inoculated intracerebrally with the scrapie RML inoculum at 4 weeks of age (30 µL of the inoculum was injected at the left hemisphere) or intraperitoneally at 7 weeks of age (with 200 µL of the inoculum). Different RML inoculum preparations were used for each experiment; therefore, some variations in incubation times are expected as a result of the disease severity during brain extraction and variability in preparations.

SIMVASTATIN ADMINISTRATION

A reported quality of simvastatin is that it efficiently penetrates the central nervous system. For a dosage of 20 mg/kg/d, a 10-mg capsule of simvastatin (Teva, Petah-Tikva, Israel) was ground and solubilized in 75 mL of acidic water at pH 5.5 (the pH of the drinking water in the specific-pathogen-free animal facility). We calculated the final drug concentration in the drinking water according to the average amount of water consumed by each mouse (approximately 5 mL/d) and the average body weight of the mature, healthy animals (approximately 33 g). Accordingly, one 10-mg capsule was solubilized in 150 mL and 750 mL to obtain concentrations of 10 and 2 mg/kg/d, respectively. A fresh simvastatin solution was added to the drinking water daily.

EXPERIMENTAL DESIGN

For intracerebrally inoculated mice, each independent experiment (total of 4) included experimental groups consisting of scrapie-infected mice and healthy controls with and without simvastatin treatment (n=15-20) (experiment 4 also included prion-infected mice and healthy controls treated with 20 mg/kg/d of l-mevalonate in parallel with the simvastatin treatment [n=4-6]). Mice were euthanized at representative times, ie, appearance of symptoms (experiment 1, 115 days post infection [dpi]; experiment 2, 105 dpi; experiment 3, 104 dpi; and experiment 4, 118 dpi [n=4-5]) or progressive disease (experiment 1, 144 dpi; experiment 2, 130 dpi; experiment 3, 136 dpi; and experiment 4, 148 dpi [n=4-5]) or when the mice were terminally ill (ie, when they were unable to reach food and water, referred to as time of death) (n=3-7). For the l-mevalonate–treated mice (experiment 4), we only determined time of death. For intraperitoneally inoculated mice (experiment 5), healthy controls and prion-infected mice were treated with either a constant low simvastatin dosage (2 mg/kg/d) or a constant high dosage (20 mg/kg/d) immediately after inoculation (n=15-17). Mice were euthanized for spleen analyses at 30 and 45 dpi. The rest of the mice were kept alive to determine disease progression and time of death. In experiments 1 through 4, mice that died during the course of the experiment due to reasons unrelated to the disease were omitted from the final analyses. Mice were observed daily for typical clinical signs of scrapie, including altered gait, kyphosis, ataxia, disorientation, somnolence, and wasting. We designated the time of scrapie symptom appearance as when at least 2 of the indicated symptoms were observed in an individual mouse for at least 4 consecutive days. In experiments 1, 3, and 4, mice were appointed to simvastatin treatment at 72 dpi. We used a protocol of increasing dosages starting at 2 mg/kg/d for 2 weeks followed by 20 mg/kg/d and continuing until termination. In experiment 2, mice were appointed to simvastatin treatment at 41 dpi. One group was treated at a low constant dosage of 2 mg/kg/d, and an additional group was treated with increasing dosages of 2, 10, and 20 mg/kg/d in 3-week intervals and then received 20 mg/kg/d until termination. Mouse brains were divided into hemispheres. One hemisphere was processed for biochemical analyses and the second was frozen immediately for cryosections.
IMUNOHISTOCHEMICAL ANALYSIS AND HEMATOXYLIN-EOSIN STAINING

Horizontal sections (8 µm thick) of frozen brain were taken between 1.5 and 2.5 mm deep (dorsal) and fixed. For bromodeoxyuridine (BrdU) staining, the sections were fixed in acetic acid, 5%, and ethanol, 95%, for 10 minutes at −20°C, followed by hydrogen peroxide, 0.3%, in methanol for 15 minutes at room temperature (mouse anti-BrdU, 1:20; Dako, Glostrup, Denmark; and neuronal nuclei antibody, 1:50; Chemicon International, Inc, Temecula, California). For ionized calcium binding adaptor molecule (IBA-1), glial fibrillary acidic protein (GFAP), and major histocompatibility complex (MHC) class II, the sections were fixed in formaldehyde, 4% (IBA-1, 1:200; Wako Chemicals, Osaka, Japan; GFAP, 1:200; Dako; and MHC class II clone IBL 5/22, 1:50; Chemicon International, Inc.). For intercellular adhesion molecule 1 (ICAM-1), sections were fixed in fresh cold acetone (1:200; Dako) and in paraformaldehyde, 4% (calbindin, 1:200; Biotechnology, Kfar Saba, Israel). Following incubation with the primary antibody (according to the manufacturers’ recommendations), sections were incubated with a goat-antimouse IgG secondary antibody conjugated to Alexa Fluor 488 (dilution, 1:100; Molecular Probes, Inc, Eugene, Oregon) for 50 minutes at room temperature or with antirabbit cy3 (dilution, 1:100; Molecular Probes, Inc.). Counterstaining was performed with 4',6-diamidino-2-phenylindole (DAPI). For the expression of MHC class II and calbindin, to measure the thickness of the CA1 neuronal layer, and to determine BrdU-immunoreactive neuronal cells, images of a total of 16 microscopic fields (4 fields for each mouse brain, at magnification ×100) containing cerebellum or hippocampal were obtained under identical conditions from each group and stored using a video camera. The positively stained cells (BrdU, MHC II) or Purkinje cells (calbindin) and the positively stained blood vessels (ICAM-1) were counted and the thickness of the CA1 layer was measured. For hematoxylin-eosin staining, sections were incubated in hematoxylin for 20 minutes at room temperature and then in ecosin, 2%, for 2 minutes at room temperature (Sigma).

BrdU INJECTIONS

Mice were intraperitoneally injected with 50 µg of BrdU per gram of body weight (RPN201; Amersham Biosciences, Buckinghamshire, England) at 12-hour intervals (3 injections starting at 104 dpi [experiment 4] or 5 injections starting at 118 dpi [experiment 5]). Mice were euthanized 12 hours after the last BrdU injection. Brains were removed and processed for immunohistochemical analysis.

FLOTATION ASSAY (RAFT ISOLATION)

Flotation of detergent-insoluble complexes was performed as described previously24 with some modifications.25 In brief, mouse brains were homogenized 1:10 wt/vol in an ice-cold buffer containing 150mM sodium chloride, 25mM TRIS hydrochloride (pH 7.5), 5mM EDTA, and Triton X-100 (Sigma), 1%. Insoluble particles were spun down and the lysate was loaded at the bottom of ultracentrifuge tubes (TLS-55; Beckman Instruments, Inc, Fullerton, California). An equal volume of ice-cold Nycodenz (Biological Industries, Beit Haemek, Israel), 70%, in TNE (25mM TRIS hydrochloride [pH 7.5], 150mM sodium chloride, and 5mM EDTA) was added and mixed with the lysate. An 8% to 35% Nycodenz linear step gradient in TNE was then overlaid above the lysate (200 µL each of 33%, 29%, 22.5%, 20%, 18%, 19%, 12%, and 8% Nycodenz). The tubes were spun at 35,000 rpm for 4 hours at 4°C in a TLS-55 rotor (200,000g). Fractions were collected from the top to the bottom of the tube. Each fraction was applied to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and immunoblotted with anti-PrP monoclonal antibody 6H4 (Prionics AG, Schlieren, Switzerland).

WESTERN BLOTTING

For the detection of PrPSc protein levels, 15-µg samples of protein measured with the bicinchoninic acid kit (Pierce Biotechnology, Rockford, Illinois) were treated with proteinase K (Sigma). Digestion was performed with 0.04-mg/mL proteinase K for 30 minutes at 37°C. PrPSc was detected with anti-PrP monoclonal antibody 6H4 (Prionics AG). For the detection of PrPSc in spleen, spleen homogenates (100 µg of protein) were treated with 0.1-mg/mL proteinase K for 1 hour at 37°C. Insoluble material was collected after ultracentrifugation at 45,000 rpm for 1 hour at 4°C and analyzed. PrPSc was detected with anti-PrP monoclonal antibody 1P1 (Sigma).

CHOLESTEROL MEASUREMENTS

Brain homogenates were prepared as described in the “Preparation of the RML Standard Inoculum” section. Five micrograms of cholesteryl acetate (internal standard) was added to samples containing 0.05 mg of protein of total brain homogenate. Samples were then extracted in 3 volumes of chloroform and methanol (2:1) for 1 hour in cold. Phases were separated by centrifugation at 2000g for 5 minutes. The lower phase was collected with careful omission of the upper phase. After evaporation of the chloroform under argon, the sample was re-suspended in 0.15 mL of isopropanol. From the sample, 0.02 mL was analyzed by high-performance liquid chromatography using a combined set of 2 columns (attached in line) (Chromolith 100/4.6 mm; RP 18e; Merck and Co, Inc, Whitehouse Station, New Jersey). Samples were separated with isopropanol and acetonitrile (1:1) at 1 mL/min with a controlled temperature set at 12°C.

STATISTICAL ANALYSES

To compare survival between prion-infected groups with and without simvastatin treatment, we used the Breslow test (SPSS version 14 statistical software; SPSS Inc, Chicago, Illinois). The different experiments and protocols did not vary in time of death; therefore, data were combined according to the experimental groups. Survival curves were determined according to Kaplan-Meier curves.

LOW-DENSITY-ARRAY REAL-TIME TAQMAN POLYMERASE CHAIN REACTION ANALYSIS

Tissue samples were snap-frozen within 5 minutes following brain removal and stored in liquid nitrogen. Total RNA was isolated by homogenization with RNeasy isolation kit (Qiagen, Valencia, California). The integrity and quantity of the RNA were evaluated using real-time polymerase chain reaction (PCR) for the housekeeping genes: 18S, glyceraldehyde-3-phosphate dehydrogenase real-time PCR experiments were carried out according to the manufacturer’s instructions (Applied Biosystems, Foster City, California). Quantitative real-time Mouse Immune Panel TaqMan PCR was performed using low-density arrays and the 7900 robotic real-time PCR system (Applied Biosystems) (see the list of 96 genes at http://docs.appliedbiosystems.com/pebiодocs/00115187.pdf). Data were collected using instrument spectral compensations by the SDS 2.2 software (Applied Biosystems) and analyzed using the threshold-cycle relative quantification method.
RESULTS

SIMVASTATIN TREATMENT INCREASED SURVIVAL IN PRION-INFECTED MICE

Healthy mice were maintained and treated in parallel with mice infected intracerebrally with RML scrapie inoculum. To study the effect of simvastatin on disease progression, the drug was administered to the mice via the drinking water. We used either a constant simvastatin dosage of 2 mg/kg/d throughout the treatment or an increasing dosage of 2 to 20 mg/kg/d. The rationale of using an increasing dosage was to overcome potential desensitization of the mice to the drug.26 Animals of each group were euthanized at times representing disease progression or kept alive to determine time of death and then euthanized at severe illness. Overall, simvastatin delayed the appearance of early prion disease symptoms by a mean (SE) of approximately 22 (5) days in mice receiving an increasing dosage of 2 to 20 mg/kg/d (n=15) and approximately 19 (4) days in mice receiving a constant dosage of 2 mg/kg/d (n=8). We refer to this delay in symptom appearance as prolonged disease incubation time. Experiments 1 through 4 did not differ statistically in survival; therefore, we combined the data from all of the 4 independent experiments. In accordance, simvastatin dosages of 2 to 20 mg/kg/d significantly increased survival of scrapie-infected mice by approximately 21 days (P < .001; n = 20–24) (Table 1 and Figure 1). The effect of the low simvastatin dosage on survival was less pronounced with approximately 14 days (n=4). To increase the certainty of the results, we used a different RML inoculum in each of the 4 experiments.

To verify the relevance of simvastatin in delayed disease progression, we also infected healthy mice intraperitoneally with RML scrapie inoculum. Mice were infected at 7 weeks of age and subjected to simvastatin treatment immediately afterward (simvastatin at constant dosages of 2 mg/kg/d or 20 mg/kg/d). Overall, both simvastatin treatments increased survival of intraperitoneally infected mice by a mean (SE) of 17 (3.5) days (n=9–10) (Table 1). In this peripheral inoculation, the increased survival can result from prolonged disease incubation time or delayed peripheral accumulation of PrPSc and delayed neuroinvasion. To this aim, we analyzed PrPSc levels in the spleens of scrapie-infected mice by immunobots. At 30 dpi, we found reduced levels of

### Table 1. Survival Increase With Simvastatin Treatment in Scrapie-Infected Mice

<table>
<thead>
<tr>
<th>Group and Inoculation</th>
<th>Time of Death, Mean (SE), dpi</th>
<th>Experiment No.</th>
<th>Time of Death, dpi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scapie infected, without simvastatin treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracerebral</td>
<td>148.4 (3.9) (n=24)</td>
<td>1^a</td>
<td>120, 150, 152, 154, 178</td>
</tr>
<tr>
<td>Intraperitoneal</td>
<td>226.4 (34.3) (n=10)</td>
<td>5^a</td>
<td>129, 229, 234, 234, 234, 234, 237, 237, 241, 241, 241</td>
</tr>
<tr>
<td>Scapie infected, with increasing simvastatin dosage of 2-20 mg/kg/d^c</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracerebral</td>
<td>166.7 (2.2) (n=20)</td>
<td>1^a</td>
<td>164, 170, 180, 184, 192</td>
</tr>
<tr>
<td>Intraperitoneal</td>
<td>243.0 (11.2) (n=10)</td>
<td>5^d</td>
<td>234, 234, 234, 234, 234, 234, 237, 237, 249, 250, 251, 251</td>
</tr>
<tr>
<td>Scapie infected, with constant simvastatin dosage of 2 mg/kg/d</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intracerebral</td>
<td>161.7 (3.5) (n=4)</td>
<td>3^b</td>
<td>151, 165, 165, 166</td>
</tr>
<tr>
<td>Intraperitoneal</td>
<td>239.1 (2.5) (n=9)</td>
<td>5^d</td>
<td>229, 234, 234, 234, 234, 234, 237, 237, 244, 251, 251, 252</td>
</tr>
</tbody>
</table>

Abbreviation: dpi, days post infection.
^a Start of simvastatin treatment at 72 dpi.
^b Start of simvastatin treatment at 41 dpi.
^c Statistically significant according to Breslow tests, P < .001.
^d Start of simvastatin treatment at 7 weeks.

![Figure 1](https://example.com) Simvastatin increased survival in prion-infected mice. Kaplan-Meier survival curve for scrapie-infected mice inoculated intracerebrally with the Rocky Mountain Laboratory inoculum, in a summary of 4 independent experiments. Simvastatin therapy at a dosage of 2 to 20 mg/kg/d was started at 72 days post infection (experiments 1, 3, and 4) or 41 days post infection (experiment 2) (n=24 and 20, respectively) (see Table 1 for experiments). ^P < .001 by the Breslow test.
PrPSc in spleens of mice treated with both simvastatin dosages, ie, 2 or 20 mg/kg/d (n = 3) (Figure 2A); at 45 dpi, reduced PrPSc levels were detected in animals treated with the high simvastatin dosage but not with the low simvastatin dosage (n = 2) (Figure 2B). This result suggests that simvastatin increased survival in intraperitoneally infected mice through delayed peripheral prion spread.

SIMVASTATIN DID NOT AFFECT BRAIN CHOLESTEROL LEVELS

We next determined brain cholesterol levels in total brain homogenates of simvastatin-treated and untreated mice. No significant alterations in cholesterol levels attributed to simvastatin treatment were detected (Table 2). Therefore, simvastatin inhibition of disease progression is independent of brain cholesterol levels.

We next analyzed the effect of simvastatin on the localization of PrPSc in brain membranes and specifically in lipid rafts. Membranal rafts containing both PrPC and PrPSc have been shown to float on Nycodenz gradients as a function of their lipid composition. Lowering cholesterol levels in vitro resulted in heavier rafts that were found in lower fractions of the gradient and affected PrP distribution to the rafts.8-10 It is therefore possible that alterations in the positioning of raft proteins in a Nycodenz gradient may represent changes in cholesterol distribution or levels in the cellular membranes. To this effect, we compared the position of PrPSc in flotation gradients in simvastatin-treated and untreated mice. PrPSc and PrPC distributions on the Nycodenz gradient were not affected by simvastatin treatment (Figure 3). Therefore, simvastatin affects disease progression through mechanisms unrelated to properties of membrane rafts.

REDUCED NEURONAL LOSS IN BRAINS OF SIMVASTATIN-TREATED, SCRAPIE-INFECTED MICE

Functional benefits derived from the pleiotropic effects of statins suggest neuroprotective effects.17 Using hematoxylin-eosin staining of frozen brain sections (105 dpi, experiment 2) untreated or treated with simvastatin were digested with proteinase K (PK) (0.04 mg/mL at 37°C for 30 minutes) and subjected to flotation gradients (see “Methods” section). Fractions were collected from the top to the bottom of the gradient, corresponding to their density, ie, low and high fractions, respectively. For the detection of PrPSc, all of the fractions were immunoblotted with anti-PrP monoclonal antibody 6H4. Healthy brains were analyzed by the flotation gradient in parallel, with the exclusion of PK digestion.

Table 2. Cholesterol Levels in Brain Homogenates of Simvastatin-Treated and Untreated Mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Cholesterol, Mean (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy, untreated (n=5)</td>
<td>35.9 (0.7)</td>
</tr>
<tr>
<td>Healthy, treated with constant simvastatin dosage of 2 mg/kg/d (n=5)</td>
<td>33.3 (2.1)</td>
</tr>
<tr>
<td>Healthy, treated with increasing simvastatin dosage of 2-20 mg/kg/d (n=5)</td>
<td>35.4 (1.5)</td>
</tr>
</tbody>
</table>

*Units are micrograms per milligram of protein.
healthy brains (Figure 4A), suggesting a neuroprotective effect of simvastatin in prion-infected brains. Importantly, no pathological effect of simvastatin treatment was observed in the healthy mice.

To confirm the effect of simvastatin treatment on Purkinje neurons in the scrapie-infected mouse brains, we stained horizontal sections containing the cerebellum for calbindin, a 28-kDa calcium-binding protein that is abundant in Purkinje neurons. As shown in Figure 4B and consistent with the hematoxylin-eosin staining results (Figure 4A), a 79% reduction in the number of Purkinje neurons was detected in the prion-infected brains. Simvastatin had a protective effect on the actual number of Purkinje neurons positively stained with calbindin in the prion-infected brains (Figure 4B).
scrapie-infected brains. There-
Inhibiting the 3-mevalonate pathway will result in a further downstream inhibition of 3-mevalonate intermediates such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate, which represents major intermediates for the posttranslational modification of proteins. One potent candidate protein for this posttranslational modification is Ras protein. On its farnesylation, Ras is activated and transported to the membranes. However, we did not detect any effect of simvastatin on Ras localization in the treated and untreated brains. We conclude that the pleiotropic effects of simvastatin are mediated through prenylation of proteins other than Ras in our prion model.

INDUCED GLIAL ACTIVATION IN BRAINS OF SIMVASTATIN-TREATED, SCRAPIE-INFECTED MICE

It is well established that the immune system has a critical role in the progression of prion pathogenesis. A typical immune response or perivascular leukocyte accumulation is absent in prions; however, glial cells were shown to be activated in Creutzfeldt-Jakob disease and a rodent model of prions. On the other hand, it was reported that simvastatin acts to inhibit neuroinflammation in neurodegeneration and specifically in prion disease.

To study the effect of simvastatin treatment on glial activation in our scrapie-infected mice, we stained frozen brain sections (105 dpi, experiment 2) of treated and untreated prion-infected mice as well as of healthy mice with anti–GFAP and IBA-1 antibodies as markers for astrocytic and microglial activation, respectively. As expected, activation of both astrocytosis and microglia was observed in the prion-infected animals throughout the brain compared with the healthy brains (Figure 7A and B). However, further activation of astrocytosis and microglia was observed in scrapie-infected, simvastatin-treated brains (Figure 7A and B), with a more pronounced induced astrocytosis than microglial activation. Therefore, the delayed disease progression and increased survival are correlated with induced astrocytosis and microglial activation. Interestingly, astrocytosis in prion-infected, simvastatin-treated mice was dose dependent, with induced activation at the constant low dosage of 2 mg/kg/d and further induction with the increasing simvastatin dosage of 2 to 20 mg/kg/d. The images in Figure 7 are taken from the dentate gyrus, a representative area indicating activation throughout the brain.

SIMVASTATIN-INDUCED MHC CLASS II ACTIVATION IN PRION-INFECTED BRAINS

We next stained healthy and scrapie-infected brains that were untreated and treated with simvastatin at early symptom appearance (118 dpi, experiment 4) for MHC class II and found that MHC class II activation correlated with glial activation. Specifically, we detected increased MHC class II activation in prion-infected brains and a further increase in prion-infected, simvastatin-treated brains (Figure 7C). Therefore, in contrast to a previous study, simvastatin treatment did not inhibit MHC class II activation; on the contrary, there is further activation of MHC class II in the treated brains. No effect on MHC class II staining was detected in healthy brains treated with simvastatin.

SIMVASTATIN INHIBITED ICAM-1 EXPRESSION IN PRION-INFECTED BRAINS

The expression of ICAM-1, a protein constitutively expressed in healthy brains, is dramatically induced by in-
flamatory conditions including proinflammatory cytokines secreted by microglia. In the inflamed brain, ICAM-1 is a marker for leukocyte infiltration, which was shown to occur in patients with Creutzfeldt-Jakob disease and in murine models of prion disease. Importantly, its expression was shown to be downregulated by simvastatin and by specific cytokines. We stained frozen brain sections of treated and untreated mice (105 dpi, experiment 2) with an anti–ICAM-1 antibody. A higher number of brain blood vessels that positively stained for ICAM-1 was detected in scrapie-infected brains than in healthy brains (Table 3). Importantly, ICAM-1 expression was downregulated by simvastatin treatment in the scrapie-infected brains. These upregulated genes may indicate T-cell activation and proinflammatory response. Interestingly, simvastatin treatment reduced Cxcl11 expression levels in the absence of a detectable effect on interferon γ levels, a result that may suggest inhibition of T-cell activation. Together, the results indicate a multifaceted effect of simvastatin, acting in parallel to induce and inhibit T-cell activation in the prion-infected brain.

Importantly, simvastatin treatment inhibited Cox2 expression in the scrapie-infected brains (Figure 8F). Cox2 is constitutively expressed in the brains and is induced on inflammation. Its expression in the brain has been associated with proinflammatory activities and involved in neurodegeneration. Therefore, its inhibition by simva-

Table 4. Simvastatin Effect on Disease Progression Is Mediated Through L-Mevalonate Pathway

<table>
<thead>
<tr>
<th>Group</th>
<th>Time of Death, Mean (SE), dpi</th>
<th>Time of Death in Experiment 5, dpi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>148.4 (3.9) (n=7)</td>
<td>143, 148, 150, 150, 153, 155, 155</td>
</tr>
<tr>
<td>Simvastatin dosage of 20 mg/kg/d</td>
<td>166.7 (2.2) (n=4)</td>
<td>169, 169, 169, 176</td>
</tr>
<tr>
<td>L-Mevalonatea</td>
<td>127.0 (13.1) (n=6)</td>
<td>86, 86, 137, 150, 150, 153</td>
</tr>
<tr>
<td>Simvastatin dosage of 20 mg/kg/d + L-mevalonateb</td>
<td>150.4 (4.1) (n=5)</td>
<td>141, 141, 153, 155, 162</td>
</tr>
</tbody>
</table>

Abbreviation: dpi, days post infection.

aSignificantly different from scrapie-infected control group; Breslow test, P<.05.
bSignificantly different from scrapie-infected mice treated with a simvastatin dosage of 20 mg/kg/d; Breslow test, P<.05.

EFFECTS OF SIMVASTATIN ON THE IMMUNE PROFILE OF PRION-INFECTED MICE

To further characterize the effects of simvastatin on the brain immune profile, we performed TaqMan low-density-array analyses (Applied Biosystems). For this, we generated complementary DNA from total brain RNA (mice euthanized at early symptom appearance; 118 dpi, experiment 4; n=4 for each group), and the immune profiles of healthy and prion-infected brains with and without simvastatin treatment were quantitatively analyzed. Expression values for target genes were normalized to the concentration of angiotensin II receptor type 2 RNA, which showed the least variation among reference genes. Among the 96 genes that were analyzed, we identified two with an expression pattern correlating with PrPSc levels, namely Cxcl10 and Ccl3, ie, the levels of these genes were upregulated in prion-infected mice and further upregulated in prion-infected, simvastatin-treated mice (data not shown). Importantly, these genes were previously shown to be upregulated in prion-infected mice. Further, we identified 6 genes that were substantially affected by simvastatin treatment in the prion-infected brains. These are Ccl2, Ccl5, Cxcr3, Cxcl11, IL1β, and Cox2 (Figure 8B). The effects on expression of these genes cannot be explained by the increased PrPSc protein levels. The expression levels of Ccl2, Ccl5, Cxcr3, and IL1β are slightly elevated in prion-infected mouse brains and substantially activated in prion-infected, simvastatin-treated mouse brains. These upregulated genes may indicate T-cell activation and proinflammatory response. Interestingly, simvastatin treatment reduced Cxcl11 expression levels in the absence of a detectable effect on interferon γ levels, a result that may suggest inhibition of T-cell activation. Together, the results indicate a multifaceted effect of simvastatin, acting in parallel to induce and inhibit T-cell activation in the prion-infected brain.
A statin may partly explain the neuroprotective effects observed.

We show that administration of simvastatin, a cholesterol-lowering drug, to prion-infected mice significantly delayed disease progression, leading to increased survival. Simvastatin affected disease progression in both peripheral (intraperitoneal) and central nervous system (intracerebral) inoculations. Interestingly, the increased incubation time occurred despite a marked increase in PrPSc levels, no detectable effect on the properties of detergent-insoluble membrane domains (ie, cholesterol-rich rafts), and no detectable effect on brain cholesterol levels. The increased survival of the prion-infected mice treated with simvastatin is associated with a striking neuroprotective effect: glial activation and cell proliferation at the hippocampus. We show that while simvastatin treatment did not affect cholesterol levels or membrane properties, its effects are mediated through the L-mevalonate pathway. Analysis of the immune profile of prion-infected, simvastatin-treated mice suggests an induced activation of astrocytes and microglia with inhibition of proinflammatory activities mediated by Cox2.

The accumulation of PrPSc is a hallmark of prion diseases, and its concentration was shown to correlate with disease severity. Nevertheless, prion disease pathogenesis and transmission were previously shown to occur in the absence of PrPSc. We show, for the first time to
our knowledge, evidence for the existence of an inverse correlation, i.e., increased levels of the pathogenic prion protein, PrPSc, despite inhibition in disease progression. We hypothesize that this unique effect is related to a larger portion of surviving scrapie-affected neurons present in the simvastatin-treated animals. These neurons may continue to generate PrPSc in the affected cells, up to the point where the prion pathogenic mechanisms overcome the neuroprotective effect conferred by the drug. These results also suggest that the neuronal toxic effects of PrPSc are dependent on additional factors, for example, factors involved in inflammation that act to induce neuronal death in prion disease.

Our in vivo results presented herein do not coincide with the in vitro results observed in cell-cultured experiments where cholesterol-lowering drugs actually affected cholesterol levels and PrPSc accumulation, resulting in lower PrPSc levels. The differences may be explained by variations in drug concentrations, efficiency of absorption, and drug clearance in the 2 experimental models.

Based on our results, we suggest that the mechanism by which simvastatin delays prion disease in the mouse model involves its pleiotropic effects.38 Importantly, we show that the beneficial effects of simvastatin are mediated through the L-mevalonate pathway. We suggest that specific protein prenylation, but not Ras farnesylation, is involved in these beneficial effects of simvastatin. In addition to their designed effect on cholesterol levels, statins induce anti-inflammatory effects39 as well as antioxidative effects.40 Together, these effects may contribute to the overall beneficial effect of simvastatin in prion diseases.

The presence of chronic inflammation in prion diseases, occurring in the absence of overt leukocyte infiltration, has been demonstrated.41 This inflammation occurs as a local response and is driven by glial cells, which have been shown to be activated in prion diseases.42 However, the primary activator of glial cells in prion diseases has not been identified and there is no direct evidence that PrPSc itself is proinflammatory.43 We report a general correlation between increased PrPSc protein levels, induced glial activation, and neuroprotection. However, in neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and prion diseases and more so in multiple sclerosis, microglial activation is correlated with neuronal degeneration.44-46 On the other hand, increasing evidence suggests that differentially activated microglial cells may have a general role in neuronal survival and neurogenesis.47-49 In this regard, we suggest that simvastatin treatment affects the secretion of chemokines and cytokines from activated microglia and astrocytes.50

Our immune profile analyses have pointed out several gene candidates for mediating a neuroprotective response. Specifically, we found increased levels of expression for Ccl2, Ccl5, Cxcr3, and Ilt1β and reduced levels for Cxcl11 and Cox2. The immune response involves a broad variety of factors; however, it is suggested that the importance of an individual factor changes during the course of a disease51 or as a result of changes in patterns of expression in other immune factors.52 Although Ccl2 and Ccl5 chemokines and Cxcr3 were shown to have a specific role as mediators of inflammation, it is sug-

Figure 8. Low-density microarray analysis of mouse immune panel. Fold changes of altered genes with a threshold expression level higher than 2 in healthy mice, healthy mice treated with simvastatin, prion-infected mice, and prion-infected mice treated with simvastatin (simvastatin dosage was 20 mg/kg/d) (n=4 brains for each group). The genes were Ccl2 (A), Ccl5 (B), Cxcr3 (C), Cxcl11 (D), Ilt1β (E), and Cox2 (F). Error bars indicate SD.
gested that specific chemokines, including Ccl2 and Ccl5, have an additional role as neuroprotective agents and that their protective action is dependent on the specific chemokine concentrations, cellular microenvironment, and stage of development of the target neuron. Recently, Cxcl11 binds with high affinity to the Cxcr3 receptor and recruits activated helper T cells, type 1, to sites of inflammation. In this regard, the finding that Cxcl11 levels are reduced while Cxcr3 levels are upregulated in simvastatin-treated, prion-infected brains may explain the neuroprotective effect of simvastatin herein. Further, it implicates more complex interactions among pivotal factors of the inflammatory response. An example of the complex effect of a specific factor is the role of interleukin-1β (IL-1β) activity in the brain. The effects of IL-1β range between promoting neuronal survival and exacerbating neuronal damage. Finally, reduced Cox2 expression supports an anti-inflammatory response in the simvastatin-treated, prion-infected mice. Based on these results, we suggest that simvastatin promotes an overall balance of microglial-induced chemokines and cytokines shifting toward neuroprotection.

Experimental manipulations of the immune system were previously shown to significantly increase survival time and delay prion disease onset. The rationale was that increased survival time serves as an indicator of slowing disease progression. However, this experimental approach was limited to the peripheral propagation of PrPSc protein and its neuroinvasion. We show that simvastatin acts to delay both the events involved in peripheral propagation as well as central nervous system–specific neurotoxic effects.

Recently, Mok et al reported that simvastatin increased survival in a murine prion model (inoculated intracerebrally). Importantly, the results from our study and that by Mok et al complement each other for prion strain (139A in the study by Mok et al and RML in our study) and mouse strain (C57B6 in the study by MOK et al and FVB/N in our study). However, the two studies differ in the protocol of drug administration: with a high simvastatin dosage of 100 mg/kg/d starting at 100 dpi and given through the mouse chow pellets (in the study by Mok et al) vs low simvastatin dosages of 2 and 2 to 20 mg/kg/d starting at 41 and 72 dpi and given through the drinking water (in our study). Importantly, despite the differences in the protocols for drug administration, the effect on survival is similar, with 16 to 20 days of increased survival in the study by Mok et al and approximately 21 days of increased survival in our study. In line with our findings, no effects on brain cholesterol levels were detected and increased survival is attributed to simvastatin’s pleiotropic effects.

However, the two studies differ significantly in the mechanisms leading to increased survival. Mok et al did not report an effect on PrPSc levels, neurosurvival, or cell proliferation, whereas we report increased PrPSc levels with simvastatin treatment and impressive effects of the drug on neuroprotection and cell proliferation in the infected brain.

Furthermore, the studies differ significantly in the results of the immune profile analyses. Whereas Mok et al reported that simvastatin acted to inhibit microglial activation (through the inhibition of MHC class II expression) in prion-infected mice, we report a more complex response to the treatment, specifically, elevation of certain factors that may indicate induced proinflammatory response (ie, GFAP, IBA-1, and MHC II expression, and upregulation of chemokines and cytokines Ccl2, Ccl5, Cxcr3, and IL-1β). In parallel, we detected inhibition of other factors that may act to inhibit the proinflammatory response, ie, downregulation of Cxcl11 and Cox2, or correlate with an inhibited inflammatory response, ie, reduced levels of ICAM-1. Collectively, our results indicate a multifaceted effect of simvastatin, inducing and inhibiting pivotal players in inflammation that together act to inhibit disease progression.

Recent studies have shown that statins act as direct inhibitors of induction of MHC class II expression by interferon γ and thus as repressors of MHC class II–mediated T-cell activation. This effect is mediated by inhibition of the inducible promoter IV of the class II transactivator. The specific disagreement in MHC class II results (in our study and the study by Mok et al) is of specific interest. Because no effect on classical proinflammatory cytokines such as interferon γ or tumor necrosis factor α was detected, simvastatin’s effects on MHC class II activation (herein) or inhibition (in the study by Mok et al) cannot be simply explained by its action to inhibit inflammatory response overall. Rather, it is more likely that a complex response with broad cellular implications is activated. The differences in observations between the two studies may result from the different drug dosages (100 mg/kg/d in the study by Mok et al vs 2-20 mg/kg/d in our study) and drug administration (chow pellets in the study by Mok et al vs drinking water in our study). In this regard, it is also important to note the effect of duration of drug administration, starting at 100 dpi in the study by Mok et al and 41 or 72 dpi in our study and present until termination. In conclusion, the two studies show results indicating that simvastatin prolongs disease incubation time and increases survival independently from its designed action to inhibit cholesterol biosynthesis. However, further study is needed to understand the alternative protective mechanisms activated by simvastatin.

To date, there is neither a cure nor a symptomatic therapy for prion diseases. Most of the experimental efforts are focusing on finding reagents that will inhibit the conversion of PrPSc to PrPSc and, thereafter, the accumulation of the abnormal prion protein isoform in cells. We show here, for the first time to our knowledge, that agents with a mechanism of action independent from PrPSc formation and accumulation can delay the onset of prion disease. Simvastatin treatment significantly delays prion disease onset in mice infected with prions. The simvastatin treatment was administered before symptom appearance; therefore, at this point, we suggest considering administering this treatment to individuals at risk such as healthy carriers of pathogenic mutations in the prion protein. While most cases of human prion diseases are sporadic, about 10% of the cases are associated with pathogenic mutations at the PrP gene. The combination of a codon 200 mutation (E200K) and the polymorphism at codon 129M is the most common form of familial...
Creutzfeldt-Jakob disease. It is particularly prevalent in Jewish persons of Libyan and Tunisian origin, who have an incidence of Creutzfeldt-Jakob disease about 100 times higher than the worldwide average.58-60

Accepted for Publication: November 12, 2007.
Correspondence: Ronit Sharon, PhD, Department of Cell Biochemistry and Human Genetics, Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel (ronitsh@ekmd.huji.ac.il).

Author Contributions: Dr Sharon had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Haviv, Ovadia, Ben-Hur, Gabizon, and Sharon. Acquisition of data: Haviv, Avrahami, Gabizon, and Sharon. Analysis and interpretation of data: Ben-Hur and Sharon. Drafting of the manuscript: Haviv, Avrahami, and Sharon. Critical revision of the manuscript for important intellectual content: Haviv, Ovadia, Ben-Hur, Gabizon, and Sharon. Statistical analysis: Sharon. Obtained funding: Gabizon and Sharon. Administrative, technical, and material support: Ben-Hur and Sharon. Study supervision: Gabizon and Sharon.

Financial Disclosure: None reported.

Funding/Support: This work was supported by the Israel Prion Center grant from the Horrowitz Foundation. Additional Contributions: Mrs Esther Reinhartz and Dr Yasmin Hamra-Amiay provided technical assistance.

REFERENCES


**Announcement**

**Trial Registration Required.** In concert with the International Committee of Medical Journal Editors (ICMJE), *Archives of Neurology* will require, as a condition of consideration for publication, registration of all trials in a public trials registry (such as http://ClinicalTrials.gov). Trials must be registered at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after July 1, 2005. For trials that began enrollment before this date, registration will be required by September 13, 2005, before considering the trial for publication. The trial registration number should be supplied at the time of submission.

For details about this new policy, and for information on how the ICMJE defines a clinical trial, see the editorial by DeAngelis et al in the January issue of *Archives of Dermatology* (2005;141:76-77). Also see the Instructions to Authors on our Web site: www.archneurol.com.

©2008 American Medical Association. All rights reserved.

Downloaded From: http://archneur.jamanetwork.com/pdfaccess.ashx?url=/data/journals/neur/7578/ on 06/26/2017